nach oben

Erschienen in:

2024 | OriginalPaper | Buchkapitel

4. Kollagenosen

verfasst von : Antonia Mazzucato-Puchner, Kastriot Kastrati

Erschienen in: Rheumatologie aus der Praxis

Verlag: Springer Berlin Heidelberg

Einloggen, um Zugang zu erhalten

Zusammenfassung

Zu den Kollagenosen gehören: der systemische Lupus erythematodes (SLE), die Mischkollagenose (Mixed Connective Tissue Disease [MCTD], Sharp-Syndrom), die systemische Sklerose (SSc), das primäre Sjögren-Syndrom (pSS) und die idiopathisch-inflammatorischen Myopathien (IIM). Der Beitrag umfasst die Beschreibung der wichtigsten Krankheiten unter Berücksichtigung der Klassifikationskriterien und neuer Erkenntnisse in der Behandlung. Mehrere Fallbeispiele tragen zum Verständnis diagnostischer Schritte und komplexer Therapieentscheidungen bei.

Vorheriges Kapitel Spondyloarthritiden

Nächstes Kapitel Familiäres Mittelmeerfieber

(1981) Preliminary criteria for the classification of systemic sclerosis (scleroderma). Bull Rheum Dis 31(1):1–6

(1980) Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 23(5):581–590

Abraham DJ et al (2009) Overview of pathogenesis of systemic sclerosis. Rheumatology (Oxford) 48 Suppl 3:iii3–iii7PubMed

Aggarwal R, Charles-Schoeman C, Schessl J (2023) Trial of intravenous immune globulin in dermatomyositis. Reply. N Engl J Med 388(1):94–95PubMedCrossRef

Andreoli L et al (2017) EULAR recommendations for women's health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome. Ann Rheum Dis 76(3):476–485PubMedCrossRef

Aringer M et al (2019) 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Ann Rheum Dis 78(9):1151–1159PubMedCrossRef

Aringer M, Hiepe F (2011) Systemic lupus erythematosus. Z Rheumatol 70(4):313–323PubMedCrossRef

Aringer M, Steiner G, Smolen JS (2005) Does mixed connective tissue disease exist? Yes. Rheum Dis Clin N Am 31(3):411–420. vCrossRef

Barbhaiya M et al (2023) The 2023 ACR/EULAR antiphospholipid syndrome classification criteria. Arthritis Rheumatol 75(10):1687–1702PubMedCrossRef

10.

Bohan A, Peter JB (1975) Polymyositis and dermatomyositis (first of two parts). N Engl J Med 292(7):344–347PubMedCrossRef

11.

Bohan A, Peter JB (1975) Polymyositis and dermatomyositis (second of two parts). N Engl J Med 292(8):403–407PubMedCrossRef

12.

Brito-Zeron P et al (2016) Early diagnosis of primary Sjogren's syndrome: EULAR-SS task force clinical recommendations. Expert Rev Clin Immunol 12(2):137–156PubMedCrossRef

13.

Bruni T, Varone F (2020) The adoption of nintedanib in systemic sclerosis: the SENSCIS study. Breathe (Sheff) 16(2):200005PubMedCrossRef

14.

Burt RK et al (2011) Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial. Lancet 378(9790):498–506PubMedCrossRef

15.

Cervera R et al (2003) Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. Medicine (Baltimore) 82(5):299–308PubMedCrossRef

16.

Dorner T (2011) Challenges in understanding Sjogren’s syndrome--improved insights into the pathogenesis generate hope for innovative therapies? Arthritis Res Ther 13(4):123PubMedPubMedCentralCrossRef

17.

Ebata S et al (2021) Safety and efficacy of rituximab in systemic sclerosis (DESIRES): a double-blind, investigator-initiated, randomised, placebo-controlled trial. Lancet Rheumatol 3(7):e489–e497PubMedCrossRef

18.

Fanouriakis A et al (2024) EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Ann Rheum Dis 83(1):15–29PubMedCrossRef

19.

Fox RI (2005) Sjogren’s syndrome. Lancet 366(9482):321–331PubMedCrossRef

20.

Fries R et al (2005) Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy. Circulation 112(19):2980–2985PubMedCrossRef

21.

Fritzler MJ, Kinsella TD (1980) The CREST syndrome: a distinct serologic entity with anticentromere antibodies. Am J Med 69(4):520–526PubMedCrossRef

22.

Hochberg MC (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40(9):1725PubMedCrossRef

23.

Hoffmann-Vold AM et al (2020) The identification and management of interstitial lung disease in systemic sclerosis: evidence-based European consensus statements. Lancet Rheumatol 2(2):e71–e83PubMedCrossRef

24.

Kastrati K et al (2024) Impact of muscle biopsy on the clinical decision-making process in patients with suspected idiopathic inflammatory myopathy. J Autoimmun 144:103185PubMedCrossRef

25.

Korn JH et al (2004) Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum 50(12):3985–3993PubMedCrossRef

26.

Kowal-Bielecka O et al (2017) Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis 76(8):1327–1339PubMedCrossRef

27.

LeRoy EC et al (1988) Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 15(2):202–205PubMed

28.

Lim J et al (2021) Intravenous immunoglobulins as first-line treatment in idiopathic inflammatory myopathies: a pilot study. Rheumatology (Oxford) 60(4):1784–1792PubMedCrossRef

29.

Lundberg IE et al (2021) Idiopathic inflammatory myopathies. Nat Rev Dis Primers 7(1):86PubMedCrossRef

30.

Matucci-Cerinic M et al (2016) Elucidating the burden of recurrent and chronic digital ulcers in systemic sclerosis: long-term results from the DUO Registry. Ann Rheum Dis 75(10):1770–1776PubMedCrossRef

31.

McHugh NJ, Tansley SL (2018) Autoantibodies in myositis. Nat Rev Rheumatol 14(5):290–302PubMedCrossRef

32.

Meijer JM et al (2010) Effectiveness of rituximab treatment in primary Sjogren’s syndrome: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 62(4):960–968PubMedCrossRef

33.

Meyer O (2006) Prognostic markers for systemic sclerosis. Joint Bone Spine 73(5):490–494PubMedCrossRef

34.

Miyakis S et al (2006) International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 4(2):295–306PubMedCrossRef

35.

Petri M et al (2012) Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 64(8):2677–2686PubMedPubMedCentralCrossRef

36.

Ramos-Casals M et al (2020) EULAR recommendations for the management of Sjogren’s syndrome with topical and systemic therapies. Ann Rheum Dis 79(1):3–18PubMedCrossRef

37.

Rubin LJ et al (2015) Riociguat for the treatment of pulmonary arterial hypertension: a long-term extension study (PATENT-2). Eur Respir J 45(5):1303–1313PubMedCrossRef

38.

Saar P, Muller-Ladner U (2006) Systemic sclerosis – a challenge in rheumatology. Z Rheumatol 65(5):429–438; quiz 439–40PubMedCrossRef

39.

Satoh M et al (2017) A comprehensive overview on myositis-specific antibodies: new and old biomarkers in idiopathic inflammatory myopathy. Clin Rev Allergy Immunol 52(1):1–19PubMedPubMedCentralCrossRef

40.

Schmidt J (2018) Current classification and management of inflammatory myopathies. J Neuromuscul Dis 5(2):109–129PubMedPubMedCentralCrossRef

41.

Sharp GC et al (1972) Mixed connective tissue disease – an apparently distinct rheumatic disease syndrome associated with a specific antibody to an extractable nuclear antigen (ENA). Am J Med 52(2):148–159PubMedCrossRef

42.

Shiboski CH et al (2017) 2016 American College of Rheumatology/European League Against Rheumatism classification criteria for primary Sjogren's syndrome: a consensus and data-driven methodology involving three international patient cohorts. Ann Rheum Dis 76(1):9–16PubMedCrossRef

43.

Specker C (2016) Antiphospholipid syndrome. Z Rheumatol 75(6):570–574PubMedCrossRef

44.

Targoff IN et al (2006) A novel autoantibody to a 155-kd protein is associated with dermatomyositis. Arthritis Rheum 54(11):3682–3689PubMedCrossRef

45.

Tektonidou MG et al (2019) EULAR recommendations for the management of antiphospholipid syndrome in adults. Ann Rheum Dis 78(10):1296–1304PubMedCrossRef

46.

Tyndall AJ et al (2010) Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis 69(10):1809–1815PubMedCrossRef

47.

van den Hoogen F et al (2013) 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Arthritis Rheum 65(11):2737–2747PubMedPubMedCentralCrossRef

48.

Witte T (2014) Sjogren’s syndrome. Z Rheumatol 73(1):49–61PubMedCrossRef

49.

Zintzaras E, Voulgarelis M, Moutsopoulos HM (2005) The risk of lymphoma development in autoimmune diseases: a meta-analysis. Arch Intern Med 165(20):2337–2344PubMedCrossRef

Titel: Kollagenosen
verfasst von: Antonia Mazzucato-Puchner
Kastriot Kastrati
Verlag: Springer Berlin Heidelberg
Buch: Rheumatologie aus der Praxis
Print ISBN: 978-3-662-69692-7

Electronic ISBN: 978-3-662-69693-4

Copyright-Jahr: 2024
DOI: https://doi.org/10.1007/978-3-662-69693-4_4

Springerpflege

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten